International: +1-347-960-6455
Synovial Sarcoma Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

According to a new research report Synovial Sarcoma Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, synovial sarcoma therapeutics currently exhibits a proliferating pipeline with 20+ therapeutic candidates.

Synovial Sarcoma Therapeutics Pipeline Insights

Synovial sarcoma is a soft-tissue sarcoma, which is divided into four stages (I, II, III, and IV) depending on the size of tumor. The growth of the tumor tends to cause numbness and pain in joints when it presses against nerves. The translocation between chromosomes X and 18 is expected to be responsible for causing this disorder. The disease can be diagnosed by genetic testing and diagnostic imagining to confirm the presence of tumors and somatic mutations.

There are three commonly used regimes for the treatment of the disease, such as surgery, radiation therapy, and chemotherapy. Among these, surgery is the most favorable treatment option for synovial sarcoma. There are no approved drugs for the primary treatment of synovial sarcoma; however, few drugs including Lartruvo (Eli Lilly and Company) and Votrient (GlaxoSmithKline plc.) are indicated for the treatment of the disease.

Insights into Pipeline Segments

According to the research findings, majority of pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.

Designation Grants by Regulatory Bodies to Accelerate the Development Process of Synovial sarcoma Therapeutics

Lavruto of GlaxoSmithKline plc was granted Orphan Drug Designation for the treatment of soft-tissue sarcoma, including synovial sarcoma in 2014 and the drug was approved for marketing in 2016. Moreover, in July 2016, Adaptimmune Therapeutics plc’s SPEAR T-cell therapy was granted Orphan Drug Designation by European Commission for the treatment of soft-tissue sarcoma.

Strategic Advancements are Expected to Drive the Synovial Sarcoma Therapeutics Pipeline

Companies that are involved in developing therapeutics for synovial sarcoma have shown active involvement in strategic collaborations to boost the development of their candidates for synovial sarcoma. For instance, in 2015, Epizyme Inc. and Eisai entered into a strategic collaboration to co-develop and market tazemetostat.

Browse Detailed Report at:

Global Market of Synovial Sarcoma Therapeutics is Expected to Increase Statistically in the next 10 years

Lartruvo (Eli Lilly and Company) and Votrient (GlaxoSmithKline plc.) are some of the drugs being used for the treatment of synovial sarcoma and with the emergence of late- and mid-stage pipeline products in the market, the overall synovial sarcoma therapeutics market is expected to grow significantly in the upcoming years.
Takara Bio Inc., GlaxoSmithKline plc, Advenchen Laboratories LLC, Epizyme Inc., Immunocore Ltd., Immune Design Corp., and Adaptimmune Limited are some of the key players involved in the development of drugs indicated for the treatment of synovial sarcoma.

Synovial Sarcoma Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of synovial sarcoma. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the synovial sarcoma therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to synovial sarcoma.